GB-400 is a Novel Patented Triple-Agent Platform with Increased Anti-Inflammatory Capabilities Targeting Psoriasis
2nd gen molecule targets psoriasis (primary target), systemic pruritis and diabetic neuropathy (secondary targets) w/ anti-inflammatory actions focus. Currently in pre-clinical phase.
- Engineered to add new MoAs.
- Conjugate of NAC + Gallic Acid and Sr2+ produce potent synergistic effects.
Quick Link
Information
Our Location
- 511 S Orange Ave #2069 Newark NJ 07103
Social Media
Copyright © 2024 All rights reserved by GalleonBio
- Privacy Policy